Press Coverage
Sofinnova Crossover
Tom Burt, partner at Sofinnova Partners, speaks at Edison Group’s Open House Global Healthcare Event
Related Strategy
CrossoverTom Burt, partner at Sofinnova Partners, joined Edison Group’s Open House Global Healthcare Event. His panel discussed some of the scenarios that are likely to play out in 2022 for biotech in public and private equity markets and M&A. View the replay here.
Related News
Abivax Announces Closing of $747.5 Million Public Offering
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
Mainstay Medical announces exclusive coverage of ReActiv8® by Anthem Blue Cross/Blue Shield
Mainstay Medical announces positive outcomes from landmark RESTORE clinical trial of ReActiv8®